Acceleron to Participate in Two Healthcare Investor Conferences in June
Get Alerts XLRN Hot Sheet
Join SI Premium – FREE
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare investor conferences in June.
|
Conference Details: |
||
| Event: | Jefferies 2017 Global Healthcare Conference | |
| Date/Time: | June 7, 2017 at 1:30 p.m. EDT | |
| Location: | New York, NY | |
| Event: | JMP Securities Life Sciences Conference | |
| Date: | June 20, 2017 | |
| Location: | New York, NY | |
A live audio webcast for the Jefferies Healthcare Conference will be available on the Investors/Media page of the Company's website at www.acceleronpharma.com. A replay of the webcast will be available approximately two hours after the event on the Acceleron website.
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. Its pioneering research platform leverages the powerful biology behind the body’s ability to rebuild and repair its own cells and tissues. This approach to drug discovery has generated four therapeutic candidates that are currently in clinical trials. The Company’s lead therapeutic candidate, luspatercept, is being evaluated in Phase 3 studies for the treatment of the hematologic diseases myelodysplastic syndromes (MDS) and beta-thalassemia under a global partnership with Celgene Corp. Acceleron is also advancing clinical programs in the fields of oncology and neuromuscular diseases and has a comprehensive preclinical research effort targeting fibrotic and other serious diseases.
For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170601005256/en/
Acceleron Pharma Inc.
Todd James, IRC, 617-649-9393
Senior
Director, Investor Relations and Corporate Communications
or
Candice
Ellis, 617-649-9226
Manager, Corporate Communications and Investor
Relations
or
Media:
BMC Communications
Brad Miles,
646-513-3125
Source: Acceleron Pharma
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NFL Star Robert Smith to Headline JumpStart VC Fest, Joining National Speaker Lineup as Startups and Venture Leaders Converge on Cleveland
- Eleven Lucosky Brookman Attorneys Recognized in The Best Lawyers in America® and Best Lawyers: Ones to Watch® in America 2027
- ArdenX Exchange – Reshaping the Standards of Digital Asset Trading
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Jefferies & Co, JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share